STRUCTURE BASED DESIGN OF NOVEL IL5 RECEPTOR ANTAGONISTS

Information

  • Research Project
  • 2867477
  • ApplicationId
    2867477
  • Core Project Number
    R43AI045249
  • Full Project Number
    1R43AI045249-01
  • Serial Number
    45249
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/1/1999 - 25 years ago
  • Project End Date
    8/31/2000 - 24 years ago
  • Program Officer Name
    PROGRAIS, LAWRENCE J.
  • Budget Start Date
    9/1/1999 - 25 years ago
  • Budget End Date
    8/31/2000 - 24 years ago
  • Fiscal Year
    1999
  • Support Year
    1
  • Suffix
  • Award Notice Date
    7/22/1999 - 25 years ago

STRUCTURE BASED DESIGN OF NOVEL IL5 RECEPTOR ANTAGONISTS

DESCRIPTION: (Adapted from the applicant's abstract) IL-5 is a T cell derived cytokine involved in the pathogenesis of atopic diseases. It specifically controls the production, activation and localization of eosinophils. Eosinophils are the major cause of tissue damage resulting in the symptoms of asthma and related allergic disorders. Thus, the design of orally bioavailable IL-5 receptor antagonists is an important area of therapeutic research for allergic asthma. Phase 1 of this project includes the following objectives: 1) generation of a 3-D dynamic model of a solvated IL-5; 2) identification of a surface aminoacyl sidechains which participate in ligand-receptor binding to generated pharmacophoric templates; 3) identification of non-peptide chemical that match the template for the described chemical properties; and 4) evaluation of biochemical and pharmacological activities of the selected small molecule IL-5 receptor antagonist candidates. Algorithms and computational tools necessary to derive these compounds have been established and implemented at Structural Bioinformatics inc. the goal of phase 2 activities aimed at refinement of the initial leads into qualified pre-clinical candidates for IL-5 antagonism PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R43
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
  • Organization Name
    CENGENT THERAPEUTICS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    SAN DIEGO
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    921271811
  • Organization District
    UNITED STATES